

Supplementary material 3: The incremental cost-effectiveness ratio in euros per event-free year for each strategy with different discounting rates. Costs were inflated to the year 2010. *Both costs and effects were discounted at the same rate

Strategies	ICER (€/year)			
	Base case	Sensitivity analysis		
	5% Discounting*	0% Discounting*	3% Discounting*	10% Discounting*
KardioPro for all risk groups	77,742	77,654	77,749	77,727
KardioPro for the CHD group	26,456	26,411	26,448	26,470
KardioPro for the high-risk group	20,901	21,174	21,017	20,626
KardioPro for the medium-risk group	52,323	52,315	52,351	52,256
KardioPro for the low-risk group	186,074	185,007	185,749	186,846

CHD: coronary heart diseases

ICER: incremental cost-effectiveness ratio